מהלך הטיפול עם רייברבנט

References
1. Rybrevant Israel MOH PI https://israeldrugs.health.gov.il/#!/medDetails/169%2046%2036954%2000
2. Park K et al. J Clin Oncol 2021. 39(30): 3391–3402.
3. Grugan K et al. MAbs 2017; 9 114–126.
4. Neijssen J et al. J Biol Chem 2021. 296 (100641); 1–13.
5. Vijayaraghavan S et al. Mol Can Ther 2020; 19(10): 2044–2056.
6. Yun J et al. Cancer Discovery 2020; 10(8): 1194–1209.
7. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated
8. https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant
9. NCCN NSCLC Guidelines. Version 3.2023
10. IASLC atlas of molecular testing for targeted therapy in lung cancer 2.2023
11. L.E. Hendriks, et al. Annals of Oncology January 2023
12. ASCO guidelines: Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations Living Guideline
13. Rybrevant US patient's website: https://www.rybrevant.com/
14. Zappa C, Mousa SA. Transl Lung Cancer Res 2016;5:288–300;
15. Riess JW, et al. J Thorac Oncol 2018;13:1560–8.
16. Lacouture ME, et al. Ann Oncol 2021;32:157–70.